#1Proposed tier Unassignedpreclinical animalAwaiting human appraisal
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Europe PMC · 2026 · PMID 41754785 · DOI 10.3390/ph19020244
preclinical-animal
Scientific intelligence record
Experience 2.0
Mitochondria-targeting peptide
Mitochondria-targeting aromatic-cationic tetrapeptide that interacts with cardiolipin; evidence is separated by disease and endpoint.
Record status
Traceability partial
Last meaningful update: 9/20/2026
Ranked research corpus
304
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
304 matching records · ranked 2026-09-18
Page 1 of 13
Europe PMC · 2026 · PMID 41754785 · DOI 10.3390/ph19020244
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1016/j.jacc.2026.02.3570 · DOI 10.1016/j.jacc.2026.02.3570
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1186/isrctn84705575 · DOI 10.1186/isrctn84705575
human-interventional
Europe PMC · 2026 · PMID 42359884 · DOI 10.18553/jmcp.2026.32.7-b.s1
human-interventional
OpenAlex · 2026 · Source ID doi:10.62225/2583049x.2026.6.4.6775 · DOI 10.62225/2583049x.2026.6.4.6775
human-observational
Europe PMC · 2026 · PMID 41934921 · DOI 10.1016/j.tice.2026.103514
preclinical-animal
Europe PMC · 2026 · PMID 42291734 · DOI 10.3389/fphys.2026.1813119
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.17615/bsca-jx31 · DOI 10.17615/bsca-jx31
laboratory-mechanistic
Europe PMC · 2026 · PMID 42361626 · DOI 10.1016/j.biopha.2026.119699
human-interventional
OpenAlex · 2026 · Source ID doi:10.65671/ft79c689 · DOI 10.65671/ft79c689
synthesis
Europe PMC · 2026 · PMID 41711592 · DOI 10.1152/ajpheart.00517.2025
preclinical-animal
Europe PMC · 2026 · PMID 42443448 · DOI 10.1007/s11064-026-04846-z
preclinical-animal
Europe PMC · 2026 · PMID 42082001 · DOI 10.1016/j.neuint.2026.106171
preclinical-animal
Europe PMC · 2026 · PMID 41206662 · DOI 10.1093/ajhp/zxaf303
contextual-unclassified
Europe PMC · 2026 · PMID 41500837 · DOI 10.1002/jimd.70132
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.2306/scienceasia1513-1874.2026.071 · DOI 10.2306/scienceasia1513-1874.2026.071
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1093/eurjpc/zwag249.037 · DOI 10.1093/eurjpc/zwag249.037
preclinical-animal
Europe PMC · 2026 · PMID 42415111 · DOI 10.1186/s13023-026-04487-z
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.64898/2026.05.27.728315 · DOI 10.64898/2026.05.27.728315
preclinical-animal
Europe PMC · 2026 · PMID 41335372 · DOI 10.1007/s40265-025-02269-8
human-interventional
WPF seed · 2026 · PMID 41335372 · DOI 10.1002/jcsm.12559
laboratory-mechanistic
Europe PMC · 2026 · PMID 41260682 · DOI 10.5582/ddt.2025.01111
human-interventional
Europe PMC · 2026 · PMID 42448476 · DOI 10.1016/j.tips.2026.06.011
contextual-unclassified
OpenAlex · 2026 · Source ID doi:10.22541/au.176942535.51579465/v1 · DOI 10.22541/au.176942535.51579465/v1
contextual-unclassified
OpenAlex · 2026 · Source ID openalex:w7161357893
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
Improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg.
FDA accelerated approval announcement1 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.
Elamipretide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Both non-standard residues are exact in notation and appear as X only in the schematic.
Sources: NIH PubChem — Elamipretide · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). Elamipretide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/elamipretide
AMA / Vancouver
World Peptide Foundation. Elamipretide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/elamipretide
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
304
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Elamipretide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasPubMed-indexed journal article; randomized controlled trial; clinical trial, phase iii; research support, n.i.h., extramural; research support, non-u.s. gov't examining genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the mmpower-3 trial. Machine-staged source candidate; findings and limitations require accountable review before publication.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2015 · study · Temporal status not established
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2019 · study · Temporal status not established
Journal of neuroinflammation
2020 · study · Temporal status not established
Proceedings of the National Academy of Sciences of the United States of America
2021 · study · Temporal status not established
Cells
2022 · study · Temporal status not established
Heart failure reviews
2022 · study · Temporal status not established
Heart failure reviews
2022 · study · Temporal status not established
Advanced healthcare materials
2022 · study · Temporal status not established
Therapeutic advances in rare disease
2023 · study · Temporal status not established
Neurology
2024 · study · Temporal status not established
Orphanet journal of rare diseases
2024 · study · Temporal status not established
Journal of the American College of Cardiology
2024 · study · Temporal status not established
Journal of the American Society of Nephrology : JASN
2024 · study · Temporal status not established
Cell communication and signaling : CCS
2025 · study · Temporal status not established
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2025 · study · Temporal status not established
Nature communications
2025 · study · Temporal status not established
International journal of molecular sciences
2025 · study · Temporal status not established
Molecular psychiatry
2025 · study · Temporal status not established
Journal of orthopaedic translation
2025 · study · Temporal status not established
Cells
2025 · study · Temporal status not established
Organogenesis
2026 · study · Temporal status not established
Drugs
2026 · study · Temporal status not established
Clinical genetics
2026 · study · Temporal status not established
Sports medicine (Auckland, N.Z.)
2026 · study · Temporal status not established
Cell metabolism
2026 · study · Temporal status not established
Bioactive materials
2026 · regulatory · Temporal status not established
European Union
2026 · regulatory · Temporal status not established
United States
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
3 represented evidence records
Years represented: 2023, 2024, 2026
Publishing organizations appearing in records: Clinical genetics, Neurology, Orphanet journal of rare diseases
3 represented evidence records
Years represented: 2023, 2024, 2026
Publishing organizations appearing in records: Clinical genetics, Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2026
Publishing organizations appearing in records: Clinical genetics, Neurology
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Elamipretide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
United States
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:17 AM
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review. 4 correction(s) have been recorded against this atlas's source metadata.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
PubMed-indexed randomized controlled trial; clinical trial, phase iii; journal article; research support, non-u.s. gov't examining efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the mmpower-3 randomized clinical trial. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; randomized controlled trial; clinical trial, phase iii; multicenter study examining effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: results from sequoia-hcm. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining elamipretide: first approval. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining ss-31@fer-1 alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining telomere length in offspring is determined by mitochondrial-nuclear communication at fertilization. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining elamipretide: a review of its structure, mechanism of action, and therapeutic potential. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review; research support, non-u.s. gov't examining targeting mitochondrial dysfunction with elamipretide. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived ipsc cardiomyocytes. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining potential therapeutic candidates for age-related macular degeneration (amd). Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; multicenter study; observational study; research support, non-u.s. gov't examining repower: an international, prospective, non-interventional registry of patients with primary mitochondrial myopathy. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, n.i.h., extramural; research support, non-u.s. gov't examining mitochondrial protein interaction landscape of ss-31. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining targeting ant1 to regulate pink1/parkin-mediated mitophagy is an effective treatment of trauma-induced tendon heterotopic ossification. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed letter; research support, non-u.s. gov't; research support, n.i.h., extramural examining genome-wide crispr screen identifies phospholipid scramblase 3 as the biological target of mitoprotective drug ss-31. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review; research support, non-u.s. gov't examining mitochondrial dysfunction: the silent catalyst of kidney disease progression. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review; research support, non-u.s. gov't examining elamipretide for barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed video-audio media; journal article; research support, non-u.s. gov't examining alcat1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining a ros-responsive liposomal composite hydrogel integrating improved mitochondrial function and pro-angiogenesis for efficient treatment of myocardial infarction. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining quality of life in barth syndrome. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining synergistic mitochondrial homeostasis regulation and cholinergic circuits reconstruction via a one-step synthesized multifunctional hydrogel facilitates spinal cord injury repair. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining ss-31 targets nos2 to enhance osteogenic differentiation in aged bmscs by restoring mitochondrial function. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining elamipretide (ss-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining novel cell-penetrating peptide targeting mitochondria. Machine-staged source candidate; findings and limitations require accountable review before publication.
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: Neurology, Orphanet journal of rare diseases
1 represented evidence record
Years represented: 2022
Publishing organizations appearing in records: Heart failure reviews
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: Nature communications